7 completed, 2 unknown, 1 recruiting, 1 terminated. 12 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow GERD: new trials by email Literature Review of GERD trials Research Report on GERD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alginate vs Sucralfate for GERD Symptomatic Relief Alginate, Sucralfate - GERD | Phase 2 / Phase 3 | Completed | CMH Lahore Medical College and Institute of Dentistry | 140 | 2025-04-01 | 2026-07-15 |
| Transoral Incisional Fundoplication (TIF) for Patients Suffering From Gastroesophageal Reflux Disease in an Asian Population Transoral incisional fundoplication - Fundoplication, GERD | Phase 2 | Recruiting | Chinese University of Hong Kong | 20 | 2021-08-01 | 2026-04-29 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
| Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery Esomeprazole, Placebo Oral Tablet - Dysphagia, GERD | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2020-07-01 | 2020-11-23 | |
| Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease JP-1366, JP-1366 placebo, Esomeprazole 40mg - GERD | Phase 2 | Completed | Onconic Therapeutics Inc. | 188 | 2019-11-15 | 2022-07-13 |
| Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease Melanole for GERD treatment, Placebo - GERD | Phase 2 / Phase 3 | Unknown | Lebanese American University | 170 | 2015-10-01 | 2015-10-28 |
| Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis CJ-12420, Esomeprazole - Erosive Esophagitis, GERD | Phase 2 | Completed | HK inno.N Corporation | 206 | 2013-05-01 | 2014-08-08 |
| Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J) PEGJ tube - GERD | Phase 2 | Terminated | Johns Hopkins University | 7 | 2012-01-01 | 2017-03-31 |
| Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms AZD3355, Placebo, Gelusil® - GERD, Acid Reflux Disease | Phase 2 | Completed | AstraZeneca | 478 | 2008-05-01 | 2011-06-20 |
| The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Esomeprazole, Budesonide - Eosinophilic Esophagitis, Gastroesophageal Reflux Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 51 | 2008-05-01 | 2016-01-14 |
| Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma Esomeprazole, Placebo - Asthma, GERD | Phase 2 | Completed | AstraZeneca | 961 | 2006-04-01 | 2014-06-09 |
| A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease XP19986 CR, Placebo for XP19986 CR - GERD | Phase 2 | Completed | Indivior Inc. | 58 | 2005-10-01 | 2016-09-14 |
Gastroesophageal Reflux (12) · Heartburn (2) · Ageusia (1) · Anosmia (1) · Anxiety Disorders (1) · Arthritis, Reactive (1) · Asthma (1) · Bipolar Disorder (1) · COVID-19 stress syndrome (1) · Deglutition Disorders (1) · Depression (1) · Eosinophilic Esophagitis (1) · Gastroparesis (1) · Glomerulonephritis (1) · Guillain-Barre Syndrome (1)
Digestive System Diseases (12) · Esophageal Diseases (12) · Esophageal Motility Disorders (12) · Gastrointestinal Diseases (12) · Deglutition Disorders (11) · Immune System Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Respiratory Tract Diseases (2) · Signs and Symptoms, Digestive (2)
Esomeprazole (5) · Alginates (1) · Budesonide (1) · Eudragit RS (1) · Gelusil (1) · Nigella sativa oil (1) · Sucralfate (1) · Sugars (1) · alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination (1) · lesogaberan (1)
AstraZeneca (2) · All Natural Medicine Clinic, LLC (1) · CMH Lahore Medical College and Institute of Dentistry (1) · Chinese University of Hong Kong (1) · HK inno.N Corporation (1) · Icahn School of Medicine at Mount Sinai (1) · Indivior Inc. (1) · Johns Hopkins University (1) · Lebanese American University (1) · Mayo Clinic (1) · Onconic Therapeutics Inc. (1)
United States (7) · South Korea (2) · Argentina (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Lebanon (1) · Mexico (1) · Pakistan (1) · Poland (1)
Amy Foxx-Orenstein, D.O. (1) · Andrew C Hecht, MD (1) · Debra Silberg, MD (1) · Hani Dimassi, PhD (1) · Hyun-Chae Jung, MD, PhD (1) · Jay Huff, M.D. (1) · Mohamad Mroueh, PhD (1) · Mouen Khashab, MD (1) · Muhammad Hafeez, MBBS (1) · Nimish Vakil, MD (1) · Rajaa Chatila, MD (1) · Wanzhu Hou, CMD (1)
PMID 20110554, PMID 22111863, PMID 23622977, PMID 23919738, PMID 25304129, PMID 27712711